Facial Injectables Market size is expected to witness appreciable growth from 2023 to 2032, owing to an increased focus on physical appearance and a noticeable upsurge in the aging population. Soaring demand for aesthetic procedures, and the increasing consumer inclination toward facial procedures, will augur well for the business landscape.
Facial injectables have become instrumental in helping rejuvenate the facial skin by diminishing the most common signs of aging, including skin folds and facial wrinkles. FDA-approved facial fillers are likely to gain traction as medical devices by the FDA are safe if applied by a board-certified cosmetic surgeon. Injectables will continue to be the most sought-after treatments, given a commendable surge in the number of people opting for online consultations globally.
The facial injectables industry could not remain untouched by the consequences of the economic slowdown. Surveys suggest that while the popularity of cosmetic procedures remains unaffected by inflation, a significant decline in middle-aged women opting for these procedures has been observed across developing countries. Plastic surgeons stress if the slowdown continues, the beauty business might face severe consequences in the U.S., U.K., and several European economies. Additionally, the client profile has also undergone significant transformation in recent years, which may further impact industry revenue streams in the coming years.
In terms of product, facial injectables market value from dermal fillers will grow by 2032 due to the progression for hyaluronic acid and collagen. Soft tissue fillers have become trendier to help create a fuller and/or smoother appearance on the face, lips, cheeks, and chin. Non-absorbable fillers have gained traction for cheek acne scars and nasolabial folds. Besides, end-users have exhibited an inclination for hyaluronic acid to enhance elasticity and increase hydration.
Based on application, lip augmentation is anticipated to account for a sizeable share of the global facial injectables market by 2032 owing to the need to treat aging signs with minimal side effects. With a rise in the smoking population, the early appearance of wrinkles and premature aging has become noticeable. End-users are likely to prefer lip augmentation to get instant results through the use of hyaluronic acid. Notably, hyaluronic acid lip injections have no artificial chemicals, as the natural tissues of the body are used for augmenting the patient’s lips.
With respect to region, the North America facial injectables market outlook will depict strong development through 2032 on the back of traction for wrinkle treatments and scar treatments across hospitals, dermatology clinics, and beauty centers. Prominently, industry participants are likely to invest in Botox and dermal fillers. Leading companies are expected to bank on technological advancements, heightened awareness about aesthetic surgical procedures, and the demand for non-invasive aesthetic procedures. Moreover, the presence of major companies is likely to drive regional expansion by 2032.
Merz Pharma, Sinclair Pharma, Johnson Medical Aesthetics, LLC, Suneva Medical, Sanofi-aventis, Allergan, Galderma S.A., and Anika Therapeutics, among others, are some of the key payers boosting the global facial injectables market.